These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3823917)

  • 1. Average relative dose intensity and the impact on design of clinical trials.
    Hryniuk WM
    Semin Oncol; 1987 Mar; 14(1):65-74. PubMed ID: 3823917
    [No Abstract]   [Full Text] [Related]  

  • 2. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of dose-dense chemotherapy in the management of breast cancer.
    Norton L
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
    Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
    Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)].
    Ariyoshi Y; Ogawa M
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
    Budman DR
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):3-9. PubMed ID: 15726532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil v cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: preliminary observations.
    Stewart DJ; Maroun JA; Hirte W; Perrault D; Stolbach L; Cripps C; Lefebvre B
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):23-7. PubMed ID: 6385261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
    Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience.
    Sledge GW
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):10-2. PubMed ID: 8629029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens.
    Genre D; Viens P; Bertucci F; Chabannon C; Gravis G; Braud AC; Camerlo J; Houvenaeghel G; Moutardier V; Goncalvez A; Protière C; Bardou VJ; Maraninchi D
    Bone Marrow Transplant; 2002 Jun; 29(11):881-6. PubMed ID: 12080351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and doxorubicin in metastatic breast cancer.
    Gehl J; Boesgaard M; Paaske T; Jensen BV; Dombernowsky P
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):35-8. PubMed ID: 8996596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-containing combination chemotherapy for metastatic breast cancer.
    Hortobagyi GN; Ibrahim N
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):53-7. PubMed ID: 8629039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
    J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity].
    Alberto P
    Bull Cancer; 1995; 82 Suppl 1():3s-8s. PubMed ID: 7626852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report].
    Izumi M; Iino Y; Yokoe T; Inoue T; Yamada T; Kobayashi I; Andoh T; Yokota T; Iijima T; Morishita Y
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):265-8. PubMed ID: 8311500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):123-5; discussion 126-9. PubMed ID: 7481854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches to adjuvant chemotherapy for breast cancer.
    Hudis C
    Pharmacotherapy; 1996; 16(3 Pt 2):88S-93S. PubMed ID: 8726587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.